
|Videos|July 15, 2021
Incorporating Esketamine into Practice for Treatment-Resistant Depression
Advertisement
Episodes in this series

Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder
2
A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care
3
Kratom Component in Clinical Trial for Opioid Use Disorder
4
Psyched Perspectives: ADHD in Underrecognized Populations, With Paige Walton, MD
5





